IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$42.25 USD
-0.14 (-0.33%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $42.23 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 81 - 100 ( 172 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Darovasertib Pathway to Approval Expected to Become More Clear in 2H21; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Darovasertib Crizotinib Combination Shows Early Promise
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update- Key Readouts Expected During 2H21. Reiterate Buy, $38 PT
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Joint GSK Synthetic Lethality Day Boosts Expectations - Raising PT to $38
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Synthetic Lethality Day Highlights: Pipeline Supported by Key Insights
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDEAYA''s Synthetic Lethality Investor Day Highlights Preclinical Data and Partnership with GSK
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Darovasertib Monotherapy and Early MEK Combination Data De-Risk Potential for Approval; Raise PT by $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
New Data for IDE196 Highlights Why It''s a Value Driver, Raising PT to $31
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First-Patient-In Announced for Phase 1 IDE397 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed with Ideaya''s MAT2A SL Candidate, Data in 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Datasets Presented at AACR Supportive of Ongoing Clinical Efforts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE196 and Synthetic Lethality Preclinical Presentations at AACR 2021 Bode Well for Clinical Studies
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E